Granocyte 34 Injection
Lenograstrim
33.6 MIU
Aventis Pharma, France
| Pack size | 34 million units vial |
|---|---|
| Unite Price | 5961.00 BDT |
Indications
Granocyte 34 Injection is used for:
Neutropenia, Reduce the risk of life-threatening infection in patients with neutropenia after cytotoxic chemotherapy.
Adult Dose
Intravenous
Neutropenia following bone marrow transplantation
Adult: 19.2 million IU/m2 or 150 mcg/m2 daily by IV infusion started the day after transplantation for a maximum of 28 consecutive days.
Subcutaneous
Mobilisation of peripheral blood progenitor cells for autologous peripheral blood stem cell transplantation
Adult: As monotherapy: 1.28 million IU/kg or 10 mcg/kg daily for 4-6 days (5-6 days in healthy donors). Following adjunctive myelosuppressive chemotherapy: 19.2 million IU/m2 or 150 mcg/m2 daily, started the day after completion of chemotherapy for a maximum of 28 consecutive days.
Chemotherapy-induced neutropenia
Adult: 19.2 million IU/m2 or 150 mcg/m2 daily, start the day after completion of chemotherapy for a maximum of 28 consecutive days.
Child Dose
Intravenous
Neutropenia following bone marrow transplantation
Child: >2 yr: 19.2 million IU/m2 or 150 mcg/m2 daily by IV infusion started the day after transplantation for a maximum of 28 consecutive days.
Renal Dose
Administration
Contra Indications
Contraindicated in patients with bone marrow cancer, children less than 2 years, and hypersensitivity.
Precautions
Premalignant or malignant myeloid condition; sickle-cell disease; osteoporotic bone disease; signs of pulmonary infiltrates (withdraw treatment). Monitor CBC during therapy. Pregnancy and lactation.
Pregnancy-Lactation
Interactions
Increased risk of myelosuppression with myelosuppressive antineoplastic agents; increased pulmonary toxicity with bleomycin and cyclophosphamide.
Side Effects
Side effects of Lenograstrim :
Musculoskeletal - Musculoskeletal pain, bone pain, splenic enlargement and osteoporosis.
Gastrointestinal - Nausea, diarrhea and loss of appetite.
Blood - Anemia and decrease in platelet counts.
Skin - Painful skin condition, skin death and skin inflammation.
Miscellaneous - Fever, headache and painful urination.
Mode of Action
Lenograstrim (rHuG-CSF) belongs to the cytokine group of biologically active proteins which regulate cell differentiation and cell growth. rHuG-CSF is a factor which stimulates the neutrophil precursor cells as demonstrated by the CFU-S and CFU-GM cell count increases in peripheral blood.
Note
Granocyte 34 33.6 MIU Injection generic name is Lenograstrim. Granocyte 34 33.6 MIU Injection is manufactured by Aventis Pharma, FranceGranocyte 34 is availble in all over Bangladesh.
Mes BD drug index information on Granocyte 34 Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.